These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29315556)

  • 1. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
    Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
    Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
    Zhang S; Chung WC; Xu K
    Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity.
    Noh HS; Hah YS; Ha JH; Kang MY; Zada S; Rha SY; Kang SS; Kim HJ; Park JY; Byun JH; Hahm JR; Shin JK; Jeong SH; Lee YJ; Kim DR
    Oncotarget; 2016 Jan; 7(4):4632-46. PubMed ID: 26716415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC‑1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity.
    Kim SO; Kim MR
    Int J Oncol; 2013 Jan; 42(1):349-58. PubMed ID: 23135610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells.
    Lee HC; Tian B; Sedivy JM; Wands JR; Kim M
    Gastroenterology; 2006 Oct; 131(4):1208-17. PubMed ID: 17030190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα.
    Yamamoto K; Tateishi K; Kudo Y; Sato T; Yamamoto S; Miyabayashi K; Matsusaka K; Asaoka Y; Ijichi H; Hirata Y; Otsuka M; Nakai Y; Isayama H; Ikenoue T; Kurokawa M; Fukayama M; Kokudo N; Omata M; Koike K
    Carcinogenesis; 2014 Nov; 35(11):2404-14. PubMed ID: 24947179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
    Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
    Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma.
    Parajuli P; Singh P; Wang Z; Li L; Eragamreddi S; Ozkan S; Ferrigno O; Prunier C; Razzaque MS; Xu K; Atfi A
    EMBO J; 2019 Jul; 38(13):e101067. PubMed ID: 31268604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Raf kinase inhibitor protein expression on pancreatic cancer cell growth and motility: an in vivo and in vitro study.
    Dai H; Chen H; Liu W; You Y; Tan J; Yang A; Lai X; Bie P
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2107-17. PubMed ID: 27444299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC).
    Karamitopoulou E; Zlobec I; Gloor B; Kondi-Pafiti A; Lugli A; Perren A
    J Transl Med; 2013 Dec; 11():311. PubMed ID: 24330423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.
    Klomp JA; Klomp JE; Stalnecker CA; Bryant KL; Edwards AC; Drizyte-Miller K; Hibshman PS; Diehl JN; Lee YS; Morales AJ; Taylor KE; Peng S; Tran NL; Herring LE; Prevatte AW; Barker NK; Hover LD; Hallin J; Chowdhury S; Coker O; Lee HM; Goodwin CM; Gautam P; Olson P; Christensen JG; Shen JP; Kopetz S; Graves LM; Lim KH; Wang-Gillam A; Wennerberg K; Cox AD; Der CJ
    Science; 2024 Jun; 384(6700):eadk0775. PubMed ID: 38843331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells.
    Li J; Wang Y; Song Y; Fu Z; Yu W
    Mol Cancer; 2014 Aug; 13():193. PubMed ID: 25128483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer.
    Li HZ; Wang Y; Gao Y; Shao J; Zhao XL; Deng WM; Liu YX; Yang J; Yao Z
    Mol Cancer Res; 2008 Jun; 6(6):917-28. PubMed ID: 18567796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
    Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY
    Carcinogenesis; 2013 Sep; 34(9):2090-8. PubMed ID: 23689354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.